The Prostate Cancer KOL Market Snapshot will address these important questions with advanced prostate cancer key opinion leaders from the US, EU and Asia Pacific to guide clinical and commercial decisions in both castrate-sensitive and castrate-resistant prostate cancer settings:
- What drives prescribing behavior of preferred treatment regimens?
- What is the level of satisfaction with existing treatment options? What are the current unmet needs?
- What is the market volatility and how likely will emerging data disrupt the current standards of care within the next 12 months and over the next 2 – 3 years?
- What are the likely catalyst(s) for treatment change in future prescribing?
This market snapshot will provide details on preferred treatment options across advanced prostate cancer settings, what drives those decisions at the mechanism and product level, what drives change in prescribing behavior.
In addition, the report will measure the level of satisfaction KOLs have with current treatment options across advanced prostate cancer settings, what is driving that satisfaction or dissatisfaction and where they see the highest unmet medical needs.
Finally, the report will explore the likelihood of disruption to current treatment options short-term (<1 yr) and mid-term (2-3 yrs) across advanced prostate cancer settings, what catalyst(s) will most likely drive changes to current prescribing behaviour.